Abstract:The effects of low-activity versus high-activity radioiodine regimens in thyroid remnant ablation for patients with differentiated thyroid carcinoma (DTC) under recombinant human thyrotropin (rhTSH) stimulation have been widely quoted but there has been no systematic review of the evidence. We undertook a systematic review of randomized controlled trials to assess the effects of low-activity radioiodine in thyroid remnant ablation in patients with DTC under rhTSH stimulation compared with high-activity radioiodine. Studies were obtained from computerized searches of MEDLINE, EMBASE, and the Cochrane Library (all until September 2012). Randomized controlled trials were included. Altogether, 637 patients with DTC who participated in three trials for residual ablation were included. Overall, studies had a low risk of bias. We found no statistically significant differences between low-activity (1.11/1.85 GBq) and high-activity (3.7 GBq) radioiodine treatment aided by rhTSH in terms of successful ablation rates on the basis of diagnostic scans [odds ratio (OR) 0.85, 95% confidence interval (CI) 0.49-1.47, P=0.56], thyroglobulin levels (OR 0.66, 95% CI 0.38-1.15, P=0.14), and health-related quality of life (mean difference 0.07, 95% CI -0.96 to 1.09, P=0.9). In addition, the subgroup analysis of 1.11 versus 3.7 GBq (OR 0.83, 95% CI 0.46-1.49, P=0.53) and 1.85 versus 3.7 GBq (OR 1, 95% CI 0.23-4.35, P=1) also showed no significant differences. The lower activity of 1.11 GBq showed significant benefit in terms of reduction in adverse events including neck pain, radiation gastritis, and salivary dysfunction during and after ablation (OR 0.63, 95% CI 0.42-0.93, P=0.02). Limited data from three randomized controlled trials suggested that an rhTSH-aided low radioiodine activity level of as low as 1.115 GBq may be sufficient for thyroid remnant ablation when compared with 3.7 GBq, with fewer common adverse effects in patients with metastasis-free DTC. Further evidence is needed to confirm the effects of low-activity radioiodine for thyroid remnant ablation. Radioiodine treatment of 1.11 GBq showed significant benefit in terms of reduction in adverse events including neck pain, radiation gastritis, and salivary dysfunction during and after ablation (OR 0.63, 95% CI 0.42-0.93, P=0.02). rhTSH-aided low radioiodine activity levels of 1.11 and 1.85 GBq are sufficient for thyroid remnant ablation as compared with 3.7 GBq, with fewer common adverse effects in patients with metastasis-free DTC. A well-designed study that compares low-activity with high-activity radioiodine ablation is needed to fully understand the long-term adverse effects and relapse or metastases. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

TSH 30 mU/L may not be necessary for successful <SUP>131</SUP>I remnant ablation in patients with differentiated thyroid cancer

TSH ≥30 mU/l may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer.

In Patients with Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 Μiu/ml is Not Adequate to Achieve Better Response to 131I Therapy.

In Patients with Low- to Intermediate-Risk Thyroid Cancer, A Preablative Thyrotropin Level of 30 Mu Iu/Ml is Not Adequate to Achieve Better Response to I-131 Therapy

Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer

The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of <SUP>131</SUP>I Treatment in DTC Patients

Sufficiency of a Single Negative Thyroglobulin Standard for Judging the Success of Ablation in Low- and Intermediate-risk Differentiated Thyroid Cancer: A Retrospective Study

Effectiveness of Different Thyroid Stimulating Hormone Thresholds for Thyroid Hormone Withdrawal - Aided Radioiodine Ablation in Patients With Differentiated Thyroid Cancer: A Systematic Review and Meta - Analysis

Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer

rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis.

Stimulating Thyroglobulin to TSH Ratio Predict Long-Term Efficacy of 131 I Therapy in Patients with Differentiated Thyroid Cancer after Total Thyroidectomy: a Retrospective Study

Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH

Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study

Analysis of Influential Factors for Efficacy of 131Ⅰ Thyroid Remnant Ablation for Differentiated Thyroid Carcinoma

Rhtsh-Aided Low-Activity Versus High-Activity Regimens of Radioiodine in Residual Ablation for Differentiated Thyroid Cancer

Radioiodine Uptake and Thyroglobulin Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-label, Controlled Trial.

Low-dose radioiodine ablation in differentiated thyroid cancer with macroscopic extrathyroidal extension and low level of preablative-stimulated thyroglobulin.

The Role of Preablative Stimulated Thyroglobulin in Guiding Risk Estimation and Therapeutic Decisions of Differentiated Thyroid Carcinoma

Predictive Value of Preablation Stimulated Thyroglobulin and Thyroglobulin/thyroid-Stimulating Hormone Ratio in Differentiated Thyroid Cancer.

Optimal Thyrotropin Level for Low-Risk Papillary Thyroid Carcinoma after Ultrasound-Guided Radiofrequency Ablation

The impact of thyroglobulin antibody on efficacy of131I ablation in patients with papillary thyroid carcinoma